Immunome

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced a recent update regarding its Investigational New Drug (IND) submission for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19).

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19 Read More
Immunome

Immunome Announces Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that it recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for IMM-BCP-01, a three-antibody …

Immunome Announces Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19 Read More

Immunome

Immunome Announces Submission for Publication of Pre-clinical Research for SARS-CoV-2 Treatment and Prophylaxis

EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that it recently submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The …

Immunome Announces Submission for Publication of Pre-clinical Research for SARS-CoV-2 Treatment and Prophylaxis Read More